Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice
| Condition(s) | Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer |
|---|---|
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Study type | Interventional |
| Summary | This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice |
| Who can participate | Inclusion Criteria: * Participants must have histologically confirmed head and neck cancer (salivary or ACC type, or squamous cell carcinoma) without evidence of recurrent, metastatic or advanced, incurable disease undergoing definitive surgical management; any stage disease is permitted (American Joint Committee on Cancer 2017 8th edition). * Age 18 years or older. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * A measurable primary tumor site both clinically and radiologically measuring at least 1 x 1 cm. \- Patients must be deemed medically fit to undergo both percutaneous and surgical procedures by their treating head and neck surgeon and medical oncologist. * Participants will undergo laboratory testing within 7 days prior to the microdevice placement: they ar |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Brigham and Women's Hospital |
| Locations | Boston, Massachusetts, United States; Boston, Massachusetts, United States |
| Start date | 2023-11-01 |
| NCT ID | NCT05553782 |
| Official listing | https://clinicaltrials.gov/study/NCT05553782 |